Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

RXi nets $13.7mm through public offering

Executive Summary

RXi Pharmaceuticals Corp. netted $13.7mm through an upsized public offering. The company sold 3.7mm units at $0.70 apiece (each unit consisted of one common share and a seven-year common share purchase warrant exercisable at $0.70) and also sold 17.7mm pre-funded units at $0.69 (each pre-funded unit held one pre-funded warrant for a common share and one seven-year common share purchase warrant exercisable at $0.70). Proceeds will support continued development of RXi's immuno-oncology projects.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies